NEWS & PRESS
Solarea Bio Announces First Close of Series B Financing Round
Solarea Bio announced today a first closing of $15m in a Series B financing led by S2G Ventures with continued participation of Bold Capital Partners, Viking Global Investors, and GG 1978 SICAF SIF.
May 08 2023
Solarea Bio Investigators Receive National Academy of Medicine Healthy Longevity 2022 Quickfire Challenge Award
Work focuses on studying the mycobiome as a novel class of probiotics for the dietary management of inflammation associated with aging.
Sep 29 2022
Solarea first peer-review publication reveals green olives and other fruits and vegetables have vast microbial diversity with the potential to deliver probiotic functionality
Solarea Bio announces its first scientific publication of some of their core research in Scientific Reports, a Nature Portfolio journal. This pilot study describes the microbial diversity known as the “Edible Plant Microbiota” in four commonly consumed items.
Dec 15 2021
Solarea Bio Teams up with Hebrew SeniorLife Investigators on a Newly Awarded U.S. National Academy of Medicine Catalyst Grant
Solarea Bio and leading researchers at Harvard Medical School affiliated Hebrew SeniorLife, New England’s largest nonprofit provider of senior health care and living communities, are co-investigators on a competitive research grant from the U.S. National Academy of Medicine’s …
Nov 04 2021
Solarea Bio Announces Licensing Agreement with ADM
Solarea Bio, a biotech company based in Cambridge, MA that is developing microbial-based solutions to aid human health, today announced it has signed a technology licensing agreement with global nutrition leader ADM.
Oct 19 2021
Solarea Bio rounds out management team to gear up for commercialization of first product
Solarea Bio, a company launching microbiome products to combat inflammatory conditions and improve the lives of afflicted individuals, rounds out their management team with strong startup commercialization experience as they welcome Dr. David Easson, Chief Manufacturing Officer and …
Oct 07 2021
Solarea Bio Announces Series A Financing
Solarea Bio announced today it has raised $11.2M in a Series A financing led by S2G Ventures and Bold Capital Partners, along with continued investment from Viking Global and additional investment from the Gisev Family Office as a syndicate …
Oct 19 2020
Welcome Solarea Bio: Innovators Unlocking the Power of Microbes to Improve Human Health
S2G’s investment into Solarea provides an opportunity for S2G to support the next wave of functional foods. S2G’s led Solarea’s Series A fundraise with Bold Capital Partners, along with continued investment from Viking Global Investors and the Gisev …
Oct 19 2020
Juliana Soto Named To Georgia Tech Alumni’s 40 Under 40 List
In the U.S., about 10 million Americans are currently living with osteoporosis or osteopenia and the majority are women. For Maria Soto-Giron, that statistic is personal. Her motivation for working in biotech looking for treatments to reduce chronic inflammation is her mother who has rheumatoid arthritis and osteoporosis.
Jul 15 2020
Eric Schott’s Ph.D. work covered by Forbes.
While your body is home to millions of different types of bacteria, it turns out that some may be more welcome than others.
But now we have more reason to believe that specific bacteria living in the gut microbiome may, in fact, be responsible for a common debilitating disease.
Apr 23 2018